Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 17

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 17
---
 patent agent. Dr. Singer’s extensive knowledge of our business and our product candidates contributed to the Board’s conclusion that he should serve as a director of our Company.

| TIMOTHY A. SPRINGER, PH.D. |     | Age | 77 |

Timothy A. Springer, Ph.D. has served as a member of our Board since June 2016 and as a scientific advisor to us since December 2008. Since 1989, Dr. Springer has served as the Latham Family Professor at Harvard Medical School. He has also served as Senior Investigator in the Program in Cellular and Molecular Medicine at Boston Children’s Hospital since 2012, and as Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Professor of Medicine at Boston Children’s Hospital since 2011. Dr. Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. Additionally, he was a founder, investor and board member of Morphic Therapeutic until its acquisition by Eli Lilly & Co. in 2024, and a founder, investor and former director of Scholar Rock, where he served as a director until May 2019. Dr. Springer is currently a founder and director of Tectonic Therapeutic since 2020 and Seismic Therapeutic since 2020. He is a founder and board member of the Institute for Protein Innovation since 2016 and trustee of the Marine Biological Laboratory since 2019 (both non-profit organizations). Dr. Springer is an elected member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer also received the Albert Lasker Basic Medical Research Award in 2022, and the Robert Koch Prize in 2023. Dr. Springer received a B.A. from the University of California, Berkeley, and a Ph.D. from Harvard University. Dr. Springer’s extensive knowledge of our business and the nanomedicine field contributed to our Board’s conclusion that he should serve as a director of our Company.

| PATRICK ZENNER, M.B.A. |     | Age | 78 |

Patrick Zenner, M.B.A. has served as a member of our Board since June 2017, also serving as our Lead Director from June 2018 to November 2019. Mr. Zenner retired